Snoot, lets see if SA can move it. The drug ACST has is almost identical to the one AMRN has and already has a FDA indication for selling it for People with triglycerides =500 mg/dL.
So I have little doubt that its TRIFECTA will be positive, but that is not until June. So I think I'll take whatever push SA can generate here and reposition a little closer to the June dates.
AMRN also is doing a reduse it study on their drug to expand the indication to all cardio, that's going to take another 3 years.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.